Abstract
A newly synthesized quinolone antimicrobial drug, balofloxacin, was administered to 4 patients with cholangitis and 2 with periproctal abscess. The clinical efficacy was excellent in 2 and good in 2 of the 4 patients with cholangitis, and excellent in 1 and good in 1 of the 2 patients with periproctal abscess. Ten strains were isolated from 6 patients (including 2 with infection with two species and 1 with infection with three species), and 8 strains were eradicated. Two strains causing biliary tract infection were decreased or persisted. No adverse effects nor abnormal changes in clinical laboratory test values, likely to be attributable to the drug, were observed in any of the patients.
